Transarterial chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma

Gastrointestinal Cancer Research

Volumn 4, Issue 1, 2011, Pages 2-8

  Kalva, Sanjeeva P ^a   Iqbal, Shams I ^a   Yeddula, Kalpana ^a   Blaszkowsky, Lawrence S ^a   Akbar, Adnan ^a   Wicky, Stephan ^a   Zhu, Andrew X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOMATERIAL; DOXORUBICIN; DOXOTUBICIN ELUTING MICROSPHERE; MICROSPHERE; UNCLASSIFIED DRUG;

ABSCESS; ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; FEVER; HEMATOMA; HOSPITALIZATION; HUMAN; INOPERABLE CANCER; KIDNEY FAILURE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CANCER; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAIN; PORTAL VEIN THROMBOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR BLEEDING;

EID: 79955572004     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. El-Serag HB: Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 37 Suppl 2: S88-94, 2007
3. Olthoff KM: Surgical options for hepatocellular carcinoma: resection and transplantation. Liver Transpl Surg 4(5 suppl 1):S98-S104, 1998
4. Verslype C, Van Cutsem E, Dicato M, et al: The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 20(suppl 7)vii1-vii6, 2009
5. Dawwas MF, Gimson AE: Candidate selection and organ allocation in liver transplantation. Semin Liver Dis 29:40-52, 2009
6. Kerr SH, Kerr DJ: Novel treatments for hepatocellular cancer. Cancer Lett 286:114-120, 2009
7. Wörns MA, Weinmann A, Schuchmann M, et al: Systemic therapies in hepatocellular carcinoma. Dig Dis 27:175-188, 2009
8. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-338, 1999
9. Wang JH, Changchien CS, Hu TH, et al: The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-Survival analysis of 3892 patients. Eur J Cancer 44:1000-1006, 2008
10. Ono Y, Yoshimasu T, Ashikaga R, et al: Longterm results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564-568, 2000
11. Soulen MC: Chemoembolization of hepatic malignancies. Oncology (Williston Park) 8:77-84; discussion 84, 89-90, 1997
12. Raoul JL, Heresbach D, Bretagne JF, et al: Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585-90, 1992
13. Bonneman B: Lipiodol-mechanism of action for chemoembolization. Jpn IVR 21:64-68, 2006
14. Johnson PJ, Kalayci C, Dobbs N, et al: Pharmacokinetics and toxicity of intraarterial Adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13:120-127, 1991
15. Lewis AL, Gonzalez MV, Lloyd AW, et al: DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335-342, 2006
16. Simonetti RG, Liberati A, Angiolini C, et al: Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8:117-136, 1997
17. Varela M, Real MI, Burrel M, et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474-481, 2007
18. Bruix J, Hessheimer AJ, Forner A, et al: New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25:3848-3856, 2006
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Bruix J, Sherman M, Llovet JM, et al: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430, 2001
21. Roayaie S, Frischer JS, Emre SH, et al: Longterm results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533-539, 2002
22. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS 2003 (http://ctep. cancer.gov), Publish Date: August 9, 2006 Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ ctcaev3.pdf.
23. Okada S: Transcatheter arterial embolization for advanced hepatocellular carcinoma: the controversy continues. Hepatology 27:1743-1744, 1998
24. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171, 2002
25. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739, 2002
26. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 332:1256-1261, 1995
27. Pelletier G, Ducreux M, Gay F, et al: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 29:129-134, 1998
28. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739, 2002
29. Cammà C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47-54, 2002
30. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171, 2002
31. Molinari M, Kachura JR, Dixon E, et al: Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol) 18:684-692, 2006
32. Kalayci C, Johnson PJ, Raby N, et al: Intraarterial Adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous Adriamycin. J Hepatol 11:349-353, 1990
33. Poon RT, Tso WK, Pang RW, et al: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100-1108, 2007
34. Malagari K, Chatzimichael K, Alexopoulou E, et al: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 31:26-80, 2008
35. Georgiades CS, Hong K, D'Angelo M, et al: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16:1653-1659, 2005
36. Marelli L, Stigliano R, Triantos C, et al: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25, 2007
37. Yoshioka H, Sato M, Sonomura T, et al: Factors associated with survival exceeding 5 years after transcatheter arterial embolization for hepatocellular carcinoma. Semin Oncol 24(2 suppl 6):S6-29-376-S6, 1997
38. Malagari K, Alexopoulou E, Chatzimichail K, et al: Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 33:512-519, 2008
39. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
40. Cheng AL, Kang Y-K, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 10:25-34, 2009